Our results suggest a potential association between OLR1 and pro-immunogenic tumor phenotypes; however, further mechanistic studies are required to elucidate the underlying molecular pathways, as well as clinical validations to determine its utility in guiding treatment decisions. The gene discussed is OLR1; the disease is neoplasm.